[Advances and experiences in economic evaluation of medicines: a complementary view].
This article presents a complementary view of the latest experiences and advances in the economic evaluation of medicines in the Spanish market. The European context and recent normative changes seem to favour the incorporation of economic evaluation of medicines as a basic tool in the decision-making process of public funding of drugs. However, some doubts remain about whether government support for economic evaluation of medicines will be open and explicit and about the role that regional decision-makers and other health actors will play in this process.
Oliva
Juan
J
Departamento de Análisis Económico, Universidad de Castilla-La Mancha, Toledo, y FEDEA, Madrid, España. juan.olivamoreno@uclm.es
Puig-Junoy
Jaume
J
Bernal
Enrique
E